Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S17 pseudogene 1 (RPS17P1)
- Target
- RPS17P1
- Molecular classification
- Other (pseudogene; not a protein-coding gene; classified as processed pseudogene)
01
Overview
Ribosomal protein S17 pseudogene 1 (RPS17P1) is a processed pseudogene related to the functional RPS17 gene, which encodes a component of the 40S ribosomal subunit involved in protein synthesis. Pseudogenes like RPS17P1 arise from reverse transcription and integration of mRNA, resulting in genomic copies that resemble protein-coding genes but generally lack the capability to produce functional proteins. RPS17P1 does not encode a functional product and has no established biological or clinical roles. It is not considered a therapeutic or clinical target, nor does it participate in known regulatory functions, pathways, or drug interactions. Its aliases include RPS17p, dJ994E9.1, and RPS17_3_674. RPS17P1 is typical of the many ribosomal protein pseudogenes found throughout the human genome, a legacy of genome evolution and retrotransposition events in primates.
- Other names
- RPS17pdJ994E9.1RPS17_3_674RPS17P1
02
Mechanism of action
None — no drugs target RPS17P1, so no mechanisms of action are known or applicable
03
Biological functions
None directly — as a pseudogene, RPS17P1 does not encode a functional protein or have established biological functions; in some cases, pseudogenes may regulate gene expression by acting as competitive endogenous RNAs, but such a function has not been described for RPS17P1
04
Disease associations
None directly — pseudogenes in general can be implicated in disease if they affect regulation, but there are no reported disease associations or clinical relevance for RPS17P1 itself
05
Safety considerations
None; as it is not a therapeutic target and has no established drug interactions or functions, there are no safety or therapeutic challenges associated with RPS17P1
06
Interacting drugs
None — there are no drugs known to interact with RPS17P1, as it does not produce a targetable protein
07
Biomarkers
None — RPS17P1 is not used as a biomarker for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Ribosomal protein S17 pseudogene 1 (RPS17P1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein S17 pseudogene 1 (RPS17P1).